This site is currently not optimized for mobile devices. For the best user experience, please access the site via a device with a wider screen such as a desktop or laptop.

For full functionality of this site it is necessary to enable JavaScript. Here are the instructions how to enable JavaScript in your web browser.

Once enabled, click here to view the site.

signup link button why should I sign up?
Login as Volunteer Login as Study team member
OR

Studies you may be eligible for. 2

Based on the information you provided, we found the following studies.

  • Phase II study of ponatinib for advanced cancers with genomic alterations in fibroblastic growth factor receptor (FGFR) and other genomic targets (KIT, PDGFRa, RET FLT3, ABL1) The purpose of this study is to find out what effects; good and/or bad, ponatinib has on you and your cancer. Your body has proteins that are involved in a cancer’s ability to grow and survive. The drug, Ponatinib, may prevent these proteins from causing cancer growth. This study is researching all of the following topics: Bladder cancer Breast cancer Colon Cancer ( Malignant tumor of colon ) Colorectal / Colon / Rectal cancer Esophagus cancer Kidney Cancer ( Malignant tumor of kidney ) Lung cancer Ovarian cancer Pancreatic cancer Prostate cancer Thyroid cancer Uterine / Uterus cancer This study is looking for: male female both men and women Volunteers with specific conditions
    • More than 18 years old
  • A Phase 2 Study of investigational drug XL184 (Cabozantinib) in Recurrent or Metastatic Endometrial Cancer Study purpose: see how useful XL184 is in treating recurrent or metastatic endometrial cancer.XL184 blocks receptors called receptor tyrosine kinases (RTKs).It is believed that by blocking these receptors from receiving signals for the tumor cells to grow, the tumor may stop growing or shrink. This study is researching all of the following topics: Uterine / Uterus cancer This study is looking for: male female both men and women Volunteers with specific conditions
    • More than 18 years old